Core--Pathology/Genotyping

核心--病理学/基因分型

• 批准号: 7102939
• 负责人: SCOTT M LIPPMAN
• 金额: $ 42.26万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7102939
• 关键词: biomedical facility; genetic screening; genotype; human genetic material tag; human tissue; neoplasm /cancer diagnosis; nucleic acid amplification techniques; nucleic acid quantitation /detection; pathology; prostate neoplasms; sample collection; tissue /cell preparation; tissue resource /registry

DESCRIPTION (provided by applicant): The Southwest Oncology Group-led Prostate Cancer Prevention Trial (PCPT) was the first large-scale chemoprevention trial for prostate cancer (PCa). This trial, which enrolled >18,800 men, tested the ability of the 5-alpha-reductase inhibitor finasteride to reduce the period-prevalence of biopsy-proven PCa over a period of 7 years. A byproduct of the PCPT was the establishment of large specimen banks of biopsy tissue, prostatectomy specimens, serum, plasma, and white blood cells obtained from the participants at the end of the study and at various interim time points during the study. The overall aim of this revised application for Core C is to establish a Pathology and Genotyping Core in support of the molecular "Biology of the PCPT" Program Project. This core will provide expertise and resources in the following areas: 1) Archival Repository Management and Distribution of the various specimen banks established from the PCPT; 2) Histopathology, including diagnostic interpretation, microtomy, microscopy, laser-capture microdissection (LCM), immunohistochemistry (IHC), and computer-assisted image analysis; and 3) Genotyping and hormone analysis, overseeing the isolation of DNA, genotyping of samples and hormone analysis to be carried out by specialized central facilities. This revised proposal addresses all of the comments from the review of the original proposal and adds new preliminary data regarding reliability and quantification of IHC, quantification of DNA extracted from serum, and extraction and amplification of DNA from paraffin-embedded tissue sections using LCM. Genotyping has also been streamlined to ensure sufficient DNA for the proposed studies and for future PCPT biology studies. Our intent is to provide the highest quality samples and pathological services to meet the needs of the research teams in the Program Project. It is our underlying hypothesis that the quality, reliability and applicability of translational research in PCa can only be guaranteed through the use of high-quality biological specimens that are handled, processed and interpreted in a uniform manner and that can be linked to clinical information and outcome.

描述（由申请人提供）：西南肿瘤学集团主导的前列腺癌 预防试验（PCPT）是前列腺癌（PCA）的第一个大规模化学预防试验。该试验招募了> 18,800名男性，测试了5-α-还原酶抑制剂非那雄胺在7年内降低活检预先验证PCA的周期性的能力。 PCPT的副产品是建立大型活检组织，前列腺切除术标本，血清，血浆和白细胞在研究结束时从参与者中获得的，以及研究期间的各个临时时间点。该修订后的核心C应用程序的总体目的是建立一种病理学和基因分型核心，以支持分子“ PCPT”计划项目。该核心将在以下领域提供专业知识和资源：1）档案存储库管理和从PCPT建立的各种标本库的分配； 2）组织病理学，包括诊断解释，显微镜，显微镜，激光捕获显微解剖（LCM），免疫组织化学（IHC）和计算机辅助图像分析； 3）基因分型和激素分析，监督DNA的分离，样品的基因分型以及由专门的中央设施进行的激素分析。该修订的建议介绍了对原始提案的审查中的所有评论，并添加了有关IHC可靠性和量化，从血清中提取的DNA的量化以及从石蜡包含的组织切片中提取和放大DNA的新初步数据。基因分型也已精简，以确保拟议研究和未来的PCPT生物学研究的足够DNA。我们的目的是提供最高质量的样本和病理服务，以满足计划项目中研究团队的需求。我们的基本假设是质量，可靠性和 翻译研究在PCA中的适用性只能通过使用以统一的方式处理，处理和解释的高质量生物标本来保证，并且可以与临床信息和结果相关。